Carotid intima-media thickness and plasma fibrinogen among subjects with metabolic syndrome: Isfahan cohort study, Iran

Zahra Bayanfar(1), Masoumeh Sadeghi(2), Ramin Heidari(3), Mojgan Gharipour(4), Mohammad Talaei(5), Akram Sedaghat(6)

Abstract

BACKGROUND: The role of plasma fibrinogen, a key regulator of inflammation processes and increased carotid intima-media thickness (cIMT) to predict metabolic syndrome (MetS) is currently under investigation. We assessed differences in the indicators of cIMT and also plasma fibrinogen level between MetS and non-MetS subjects. We also assessed the role of these two parameters for independently relationship with MetS state.

METHODS: The subjects in this cross-sectional survey were population-based samples of 93 men and women aged ≥ 35 years and over who were selected from the Isfahan cohort study, Isfahan, Iran. Fibrinogen was measured by the clotting assay of Clauss. Ultrasound studies of the carotid artery were performed to measure cIMT. MetS defined based on the National Cholesterol Education Program’s Adult Treatment Panel III.

RESULTS: The mean level of plasma fibrinogen was not different in the two groups with and without MetS (240.10 ± 27.80 vs. 242.56 ± 35.82, P = 0.714), but the mean of cIMT was considerably higher in MetS group than in non-MetS group (0.85 ± 0.06 mm vs. 0.66 ± 0.09 mm, P < 0.001). Using a multivariable logistic regression model, high cIMT could effectively predict MetS state with the presence of different components of MetS (odds ratio = 17.544, 95% confidence interval = 2.151-142.860, P = 0.008). The optimal cutoff point of cIMT for discriminating these two clinical states was 0.6 mm yielding a sensitivity of 61.5% and a specificity of 59.6%.

CONCLUSION: Individuals with MetS demonstrated increased cIMT values compared with those without MetS. However, high plasma fibrinogen level may not be associated with MetS state.

Keywords: Metabolic Syndrome, Carotid Intima-Media Thickness, Fibrinogen, Prediction

Introduction

Subclinical atherosclerosis in great vessels is one of the clear identified results of cardio-metabolic abnormalities like metabolic syndrome (MetS). One of the most important atherosclerotic-mediated changes is increased carotid intima-media thickness (cIMT) and hence has been agreed as a well-established surrogate index of coronary and cerebral atherosclerotic events.1 According to recent evidences, this vascular event can be shown following appearance of MetS and its progression may be also prevented by spontaneous recovery from this syndrome.2 Even, it has been indicated that MetS is more predictive of cIMT than the sum of the individual components of the syndrome.3,4 However, while there are some reports that increased cIMT may not be associated with each of MetS components such as insulin resistance.5 In this

Date of submission: 24 Mar 2014, Date of acceptance: 10 May 2014
regard, evidences on associations between MetS and atherosclerosis as well as increased cIMT are eagerly waited for.

The role of plasma fibrinogen, a key regulator of inflammation processes, as a cardiovascular risk factor remains controversial. Some surveys could demonstrate that higher plasma fibrinogen concentrations were associated with a greater incidence of coronary heart disease and its progression.\textsuperscript{6-10} Besides, increased age-adjusted plasma level of fibrinogen has been revealed to be associated with a cluster of cardiovascular risk factors and MetS components including obesity, high blood pressure, and dyslipidemia.\textsuperscript{11} It is evidenced that some major components of MetS such as central obesity may be linked to elevation in plasma fibrinogen concentration through the mediation of blood pressure, C-reactive protein, as well as via being affected by cigarette smoking.\textsuperscript{12} In this context, considering hyperfibrinogenemia as a main component of MetS has been recently recommended.

In the present study, we followed two targets: first, we assessed differences in the indicators of cIMT and also plasma fibrinogen level between MetS and non-MetS subjects. Second, we assessed the role of these two parameters for independently predicting MetS state.

**Materials and Methods**

The subjects in this cross-sectional survey were population-based samples of 93 men and women aged \( \geq 35 \) years and over (power of study: 80\%, \( \alpha = 5\% \)) who were selected by random sampling from the Isfahan, Iran, cohort study that was performed in 2001 in three central provinces in Iran, including Isfahan, Arak, and Najafabad and enrolled 6504 participants with the aim of detecting the incidence of cardiovascular diseases and its-related major risk factors.\textsuperscript{13} The subjects with a history of any cardiovascular or related disorders, pregnant women, breastfeeding mothers, and those subjects with serious systemic illnesses from the study. The protocol of this study was approved by the Research and Ethics Committees of the Isfahan Cardiovascular Research Institute. The individuals enrolled in this study were informed about the aims of the investigation and those who agreed signed informed consent forms. All participants were asked to fast for 8-12 h before attending the first visit in order to obtain demographics information, medical history, to conduct clinical examination and venous blood samples for lab tests. In this regard, venous blood samples were drawn in vacuum tubes containing sodium citrate as an anticoagulant. Blood samples were centrifuged at 2500 rpm for 10 min to obtain plasma. The plasma was separated and stored at 70 °C for 2 weeks until the measurement. Fibrinogen was measured by the clotting assay of Clauss,\textsuperscript{14} using a commercially available kit in the same laboratory. Serum total cholesterol was measured by enzymatic methods, and high-density lipoprotein (HDL) cholesterol was measured after heparin-manganese precipitation using the Liebermann–Burchard method using an autoanalyzer (Eppendorf, Hamburg, Germany). Hypercholesterolemia was defined as total cholesterol \( \geq 240 \) mg/dl, HDL-cholesterol \( < 40 \) mg/dl in men, and \( < 50 \) mg/dl in women, triglycerides \( \geq 240 \) mg/dl.\textsuperscript{15} Serum glucose was measured by enzymatic methods. Diabetes mellitus was defined as serum glucose of 140 mg/dl or more fasting and/or blood glucose of 200 mg/dl or more non-fasting and/or taking hypoglycemic medication.\textsuperscript{15} Measurement of blood pressure and anthropometric parameters were carried out following standard protocols.\textsuperscript{16,17} Height in stocking feet and weight in light clothing were measured, and body mass index was calculated as weight (kg)/height (m\(^2\)) using Seca Stadiometer (Germany, 2009). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured with a standard mercury sphygmomanometer on the right arm of seated participants after a 5-min rest. Hypertension was defined as SBP of 140 mmHg or more and/or DBP of 90 mmHg or more and/or taking antihypertensive medication.\textsuperscript{15} MetS was defined based on the presence of three or more components of the defined criteria for MetS by the amended National Cholesterol Education Program’s Adult Treatment Panel III (ATP-III).\textsuperscript{16} The ATP-III criteria include: (1) fasting triglycerides \( > 150 \) mg/dl or lipid medications; (2) SBP \( > 130 \) mmHg, DBP \( > 85 \) mmHg, or use of antihypertensive medications; (3) fasting plasma glucose \( > 110 \) mg/dl or use of diabetes medications; (4) HDL cholesterol \( < 40 \) mg/dl (men) or \( < 50 \) mg/dl (women); and (5) waist circumference \( > 102 \) cm (men) or \( > 88 \) cm (women). Using the previous criteria we found 39 patients who were diagnosed to have MetS and 54 patients without MetS. Ultrasound studies of the carotid artery were performed to measure cIMT from the posterior wall of the left common carotid artery about 10 mm proximal from the bifurcation.\textsuperscript{17} Incident high cIMT or plaque was defined as those with cIMT \( \geq 90^{th} \) percentile\textsuperscript{18} that was estimated 0.75 in the present study by one observation.
Shapiro–Wilk and Kolmogorov–Smirnov test was used to check the normality of data distribution. Bartlett’s test was used to check the homogeneity of variances. Differences in sex-specific mean values and proportions of baseline characteristics were compared between people who developed MetS and those who remained free of MetS by using a t-test or chi-square test. Logistic regression models were used to examine the relations of plasma fibrinogen and cIMT with the incidence of MetS. Correlation between the quantitative variables was tested by the Pearson’s test. The characteristics of study subjects by MetS status and those without MetS are presented in Table 1; 39 subjects (41.9%) had MetS. The two study groups were not different in the two groups with and without MetS. For the statistical analysis, the mean level of plasma fibrinogen was higher in MetS group than in non-MetS group (44.82 ± 8.87 vs. 47.31 ± 8.87, P = 0.078), but the mean of cIMT was considerably higher in MetS group than in non-MetS group (240.10 ± 27.80 mm vs. 242.56 ± 35.82, P = 0.013). Applying a linear regression modeling, among different definitive components of MetS, higher waist to hip ratio (β = 0.331, standard error (SE) = 0.138, P = 0.029), serum total cholesterol level (β = 0.002, SE = 0.001, P = 0.021), and high LDL cholesterol level (β = 0.002, SE = 0.001, P = 0.040) were positively associated with cIMT. However, none of the MetS components was associated with the level of plasma fibrinogen.

Considering 0.75 mm as the cut-off for high cIMT showed higher incidence of high cIMT in MetS group compared with non-MetS group (25.6% vs. 1.9%, P < 0.001). No significant association was revealed between plasma level of fibrinogen and cIMT in both MetS group (r = 0.018, P = 0.913) and non-MetS group (r = −0.052, P = 0.714). Using a multivariable logistic regression model (Table 2), it was shown that high cIMT could effectively predict MetS state with the presence of different components of MetS [odds ratio = 17.544, 95% confidence interval (CI) = 2.151-142.860, P = 0.008]. In this context, high level of plasma fibrinogen was not a determinant for MetS status. Applying the ROC curve analysis (Figure 1), cIMT measurement had an acceptable value for discriminating MetS from non-MetS states [Area under curve (AUC) = 0.746, 95% CI = 0.644-0.848, P < 0.001]. The optimal cut-off point of cIMT for discriminating these two clinical states (Figure 2) was 0.6 mm yielding a sensitivity of 61.5% and a specificity of 59.6%.

**Results**

The characteristics of study subjects by MetS status and those without MetS are presented in table 1; 39 subjects (41.9%) had MetS. The two study groups were statistically similar in the average age, history of smoking, and serum level of low-density lipoprotein (LDL); while those with MetS were more female as well as had a higher prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus. The mean level of plasma fibrinogen was not different in the two groups with and without MetS (240.10 ± 27.80 vs. 242.56 ± 35.82, P = 0.714), but the mean of cIMT was considerably higher in MetS group than in non-MetS group (0.85 ± 0.06 mm vs. 0.66 ± 0.09 mm, P < 0.001). Applying a linear regression modeling, among different definitive components of MetS, higher waist to hip ratio (β = 0.331, standard error (SE) = 0.138, P = 0.029), serum total cholesterol level (β = 0.002, SE = 0.001, P = 0.021), and high LDL cholesterol level (β = 0.002, SE = 0.001, P = 0.040) were positively associated with cIMT. However, none of the MetS components was associated with the level of plasma fibrinogen.

Considering 0.75 mm as the cut-off for high cIMT showed higher incidence of high cIMT in MetS group compared with non-MetS group (25.6% vs. 1.9%, P < 0.001). No significant association was revealed between plasma level of fibrinogen and cIMT in both MetS group (r = 0.018, P = 0.913) and non-MetS group (r = −0.052, P = 0.714). Using a multivariable logistic regression model (Table 2), it was shown that high cIMT could effectively predict MetS state with the presence of different components of MetS [odds ratio = 17.544, 95% confidence interval (CI) = 2.151-142.860, P = 0.008]. In this context, high level of plasma fibrinogen was not a determinant for MetS status. Applying the ROC curve analysis (Figure 1), cIMT measurement had an acceptable value for discriminating MetS from non-MetS states [Area under curve (AUC) = 0.746, 95% CI = 0.644-0.848, P < 0.001]. The optimal cut-off point of cIMT for discriminating these two clinical states (Figure 2) was 0.6 mm yielding a sensitivity of 61.5% and a specificity of 59.6%.

**Table 1. Baseline data in two groups with and without metabolic syndrome**

| Characteristics                  | Group with MetS (n = 39) | Group without MetS (n = 54) | P    |
|----------------------------------|-------------------------|----------------------------|------|
| Male gender                      | 15 (38.5)               | 35 (67.3)                  | 0.006|
| Hyperlipidemia                   | 35 (89.7)               | 25 (48.1)                  | < 0.001|
| Diabetes mellitus                | 8 (20.5)                | 3 (5.8)                    | 0.033|
| Hypertension                     | 17 (43.6)               | 7 (13.5)                   | 0.001|
| Cigarette smoking                | 7 (17.9)                | 18 (34.6)                  | 0.078|
| High intima-media thickness      | 10 (25.6)               | 1 (1.9)                    | 0.001|
| Body mass index (kg/m²)          | 32.46 ± 5.52            | 26.71 ± 5.26               | < 0.001|
| Waist to hip ratio               | 0.97 ± 0.06             | 0.89 ± 0.06                | < 0.001|
| Fasting blood sugar (mg/dl)       | 100.87 ± 44.75          | 84.88 ± 14.35              | 0.018|
| Total cholesterol (mg/dl)         | 210.56 ± 41.79          | 193.33 ± 29.55             | 0.023|
| Serum triglyceride (mg/dl)        | 244.36 ± 134.56        | 119.06 ± 48.25             | < 0.001|
| HDL (mg/dl)                      | 41.41 ± 9.67            | 47.83 ± 11.77              | 0.005|
| LDL (mg/dl)                      | 117.90 ± 24.87          | 111.67 ± 19.64             | 0.201|
| SBP (mmHg)                       | 133.83 ± 19.38          | 119.62 ± 15.01             | < 0.001|
| DBP (mmHg)                       | 84.10 ± 10.06           | 76.63 ± 7.90               | < 0.001|
| Plasma fibrinogen                | 240.10 ± 27.80          | 242.56 ± 35.82             | 0.083|
| Intima-media thickness (mm)      | 0.85 ± 0.06             | 0.66 ± 0.09                | < 0.001|
| Age (year)                       | 44.82 ± 6.09            | 47.31 ± 8.87               | 0.136|

MetS: Metabolic syndrome; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; SBP: Systolic blood pressure; DBP: Diastolic blood pressure.
Table 2. Multivariate logistic regression model for determining value of high intima-media thickness and plasma fibrinogen to predict metabolic syndrome

| Variables             | P       | Odds ratio | 95% Confidence interval |
|-----------------------|---------|------------|-------------------------|
| High intima-media thickness | 0.008   | 17.544     | 2.151-142.860           |
| Plasma fibrinogen     | 0.395   | 0.991      | 0.970-1.012             |
| Male gender           | 0.095   | 0.228      | 0.040-1.293             |
| Age                   | 0.139   | 0.906      | 0.796-1.032             |
| Body mass index       | 0.028   | 1.210      | 1.021-1.435             |
| Hyperlipidemia        | < 0.001 | 35.546     | 4.889-258.443           |
| Diabetes mellitus     | 0.670   | 1.603      | 0.184-13.991            |
| Hypertension          | 0.007   | 15.848     | 2.093-119.993           |
| Cigarette smoking     | 0.696   | 1.462      | 0.217-9.846             |

Hosmer–Lemeshow goodness of fit: $\chi^2 = 20.564; P = 0.008$

Discussion

MetS significantly associated with increased cIMT in our cross-sectional study sourced from Isfahan prospective cohort analysis, and the association between MetS and incident high cIMT was considerably attenuated after controlling or different components of MetS in a multivariate logistic regression model. These findings suggest that the high cIMT can be an integral part of MetS. A variety of studies could show association between MetS and high cIMT. Reinehr et al. showed in subjects with MetS demonstrated increased intima-media thickness (IMT) values compared those without MetS. In another study, MetS strongly predicted incident high cIMT, defined as cIMT > 90th percentile and/or plaque. In this regard, it is now suggested that a combination of different components of MetS may have synergistic effects on existence and progression of carotid plaques resulting increased cIMT. Timoteo et al. could demonstrate that advanced age, male gender, insulin, and HDL cholesterol were independent predictors of cIMT. They showed that in patients without MetS, only age and HDL cholesterol were associated; while, in MetS group, independent predictors were age, male gender, and high serum glucose. Tonstad et al. suggested that the classic lipid and hemostatic risk factors, as well as plasma total homocysteine, were associated with markers of early carotid atherosclerosis from the second decade of life. According to the results of the Framingham study, the introduced Framingham risk factors accounted for 28.6% and 27.5% of the variability in the common carotid artery and internal carotid artery IMT, respectively. Furthermore, age and gender contributed 23.5% to the variability of the common carotid artery IMT and 22.5% to that of the internal carotid artery IMT, with the next most important factor being SBP (1.9%) for the common carotid artery IMT and smoking (1.6%) for the internal carotid artery IMT. In another observation by Shiri et al., obesity, high LDL cholesterol, high triglycerides, hypertension and cardiac arrhythmia were associated with increased IMT in subjects aged 30-44. Oren et al. also showed that
age, body mass index, pulse pressure, sex, and LDL cholesterol level were independent determinants of increased cIMT in young adults. In our survey, higher waist to hip ratio, high serum total cholesterol level, and high LDL cholesterol level were positively associated with cIMT that is consistent with several previous studies.

Regarding the association between MetS state and plasma fibrinogen level, we found no significant association between these two parameters. On the other hand, although relation between inflammatory processes and MetS has been shown in some studies, but association between fibrinogen as an inflammatory index and MetS and its-related components was not meaningful in our study. Imperatore et al. showed that age-adjusted fibrinogen levels correlated significantly with obesity, SBP and DBP, plasma total cholesterol, LDL cholesterol, triglycerides, insulin, and HDL cholesterol inversely. In a study by Ford, participants with the MetS had higher fibrinogen concentrations than those without this syndrome. Besides, the association between fibrinogen level and MetS was only demonstrated in women, not in men in Onat et al. study. On the other hand, MetS was not significantly predicted by fibrinogen levels in women in either multivariable model and thus plasma fibrinogen predicts MetS independently of its components in men, in contradistinction to women. It seems that our paradoxical findings may be affected by different factors such as selecting a population with a narrow range for plasma fibrinogen concentration, a wide range of the patients’ age, as well as considering a partial small sample size and therefore achieving a moderate study power. Hence, for more investigation of the association of plasma fibrinogen concentration and MetS state, further studies should be conducted in our population.

Our results are limited to our small size but in this is the first report in Iranian sample, which focused on the relationship of cIMT and fibrinogen and would be provide a view of the procedure in this population.

**Conclusion**

Our study demonstrate that measuring cIMT can help to predict MetS state, however measuring plasma fibrinogen has no this potential predictive role. In fact, association between MetS and cIMT can be mediated by the presence of some MetS components including waist to hip ratio, high serum total cholesterol level, and high LDL cholesterol level.

**Acknowledgments**

This study was conducted as thesis. We are thankful to the team of the ICRC, Isfahan Provincial Health Center, Najaf-Abad Health Office and the Arak University of Medical Sciences.

**Conflict of Interests**

Authors have no conflict of interests.

**References**

1. Kotani K, Shimohiro H, Adachi S, Sakane N. Relationship between lipoprotein(a), metabolic syndrome, and carotid atherosclerosis in older Japanese people. Gerontology 2008; 54(6): 361-4.
2. Mattsson N, Ronnemaa T, Juonala M, Viikari JS, Jokinen E, Hutri-Kahonen N, et al. Arterial structure and function in young adults with the metabolic syndrome: the Cardiovascular Risk in Young Finns Study. Eur Heart J 2008; 29(6): 784-91.
3. Koskinen J, Magnussen CG, Tafttonen L, Rasanen L, Mikkila V, Laitinen T, et al. Arterial structure and function after recovery from the metabolic syndrome: the cardiovascular risk in Young Finns Study. Circulation 2010; 121(3): 392-400.
4. Reinehr T, Wunsch R, Putter C, Scherag A. Relationship between carotid intima-media thickness and metabolic syndrome in adolescents. J Pediatr 2013; 163(2): 327-32.
5. Panacciulli N, de Pergola G, Ciccone M, Rizzon P, Giorgino F, Giorgino R. Effect of family history of type 2 diabetes on the intima-media thickness of the common carotid artery in normal-weight, overweight, and obese glucose-tolerant young adults. Diabetes Care 2003; 26(4): 1230-4.
6. Kawamoto R, Tomita H, Ohtsuka N, Inoue A, Kamitani A. Metabolic syndrome, diabetes and subclinical atherosclerosis as assessed by carotid intima-media thickness. J Atheroscler Thromb 2007; 14(2): 78-85.
7. Sato S, Kobayashi T, Iida M, Naito Y, Kiyama M, Kitamura A, et al. A case-reference study on plasma fibrinogen concentrations and coronary atherosclerosis in Japanese. J Epidemiol 1996; 6(2): 81-6.
8. Onohara T, Komori K, Kume M, Ishida M, Ohta S, Takeuchi K, et al. Increased plasma fibrinogen level and future risk of coronary artery disease after repair of abdominal aortic aneurysm. J Am Coll Surg 2000; 191(6): 619-25.
9. Sweetnam PM, Thomas HF, Yarnell JW, Beswick AD, Baker IA, Elwood PC. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. Eur Heart J 1996; 17(12): 1814-20.
10. Yarnell JW, Baker IA, Sweetnam PM, Bainton D,
O’Brien JR, Whitehead PJ, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991; 83(3): 836-44.

11. Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study. Diabetes Care 1998; 21(4): 649-54.

12. Onat A, Ozhan H, Erbilen E, Albayrak S, Kucukdurmaz Z, Can G, et al. Independent prediction of metabolic syndrome by plasma fibrinogen in men, and predictors of elevated levels. Int J Cardiol 2009; 135(2): 211-7.

13. Sarrafzadegan N, Talaei M, Sadeghi M, Kelishadi R, Oveisgharan S, MohammadiFard N, et al. The Isfahan cohort study: rationale, methods and main findings. J Hum Hypertens 2011; 25(9): 545-53.

14. Barthels M. Diagnostic of blood coagulation. Hamostaseologie 2008; 28(5): 320-34.

15. Gharipour M, Sarrafzadegan N, Sadeghi M, Andalib E, Talaei M, Shafie D, et al. Predictors of metabolic syndrome in the Iranian population: waist circumference, body mass index, or waist to hip ratio? Cholesterol 2013; 2013: 198384.

16. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143-421.

17. Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Maki-Torkko N, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290(17): 2277-83.

18. Mattsson N, Magnussen CG, Ronnemaa T, Mallat Z, Benessiano J, Jula A, et al. Metabolic syndrome and carotid intima-media thickness in young adults: roles of apolipoprotein B, apolipoprotein A-I, C-reactive protein, and secretory phospholipase A2: the cardiovascular risk in young Finns study. Arterioscler Thromb Vasc Biol 2010; 30(9): 1861-6.

19. Timoteo AT, Carmo MM, Ferreira RC. Can metabolic syndrome presence predict carotid intima-media thickness? J Clin Hypertens (Greenwich) 2012; 14(8): 507-13.

20. Tonstad S, Joakimsen O, Stensland-Bugge E, Leren TP, Ose L, Russell D, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol 1996; 16(8): 984-91.

21. Polak JF, Pencina MJ, Meisner A, Pencina KM, Brown LS, Wolf PA, et al. Associations of carotid artery intima-media thickness (IMT) with risk factors and prevalent cardiovascular disease: comparison of mean common carotid artery IMT with maximum internal carotid artery IMT. J Ultrasound Med 2010; 29(12): 1759-68.

22. Shiri R, Heliovaara M, Moilanen L, Viikari J, Liira H, Viikari-Juntura E. Associations of cardiovascular risk factors, carotid intima-media thickness and manifest atherosclerotic vascular disease with carpal tunnel syndrome. BMC Musculoskelet Disord 2011; 12: 80.

23. Oren A, Vos LE, Uiterwaal CS, Grobbee DE, Bots ML. Cardiovascular risk factors and increased carotid intima-media thickness in healthy young adults: the Atherosclerosis Risk in Young Adults (ARYA) Study. Arch Intern Med 2003; 163(15): 1787-92.

24. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003; 168(2): 351-8.

How to cite this article: Bayanfar Z, Sadeghi M, Heidari R, Gharipour M, Talaei M, Sedaghpat A. Carotid intima-media thickness and plasma fibrinogen among subjects with metabolic syndrome: Isfahan cohort study. ARYA Atheroscler 2014; 10(5): 238-43.